< Key Hightlight >

MARKET OUTLOOK 

Based on a study by Triton Market Research, the Alzheimer’s disease therapeutics and diagnostics market in the Asia-Pacific is expected to rise with a CAGR of 8.14% over the forecast years from 2021-2028. China, India, Japan, Australia & New Zealand, South Korea, ASEAN countries, and Rest of Asia-Pacific together shape the market in this region.

Data from the United Nations Population Fund 2017 report indicates that 0.9 million senior citizens in India were affected by dementia in 2011. This number is expected to rise to 1.7 million by 2030. The Indian healthcare system is seeing immense development, thanks to the growing economy. Therefore, the demand for technological advancements in healthcare for the early diagnosis and treatment of dementia and cognitive impairment is also rising. This is expected to foster the growth of the Alzheimer’s disease therapeutics and diagnostics market throughout the country in the coming years.

In 2010, the “Dementia Supporters Training Program” was launched in South Korea to spread awareness about dementia and encourage the public to support the people suffering from the condition, as per Alzheimer’s Disease International. Also, the government of the country introduced new long-term care insurance to fund initiatives such as these, after assessing the rate of its growing aging population. These factors are expected to boost the Korean market’s growth in the projected period.

COMPETITIVE OUTLOOK

The leading players in the Alzheimer’s disease therapeutics and diagnostics market include Biogen Inc, Luye Pharma Group, Zydus Cadila, Teva Pharmaceutical Industries Limited, PeopleBio Co, Eisai Co Ltd, Cognoptix Inc, Allergan Plc acquired by Abbvie, Pfizer Inc, and Eli Lilly & Company.